COVID-19患者における免疫性血小板減少性紫斑病

Immune Thrombocytopenic Purpura in Patients with COVID-19.

• Sabine Revuz
• Nathalie Vernier
• Leilah Saadi
• Julien Campagne
• Sophie Poussing
• François Maurier

抄録

COVID-19に感染した3例の重篤な免疫性血小板減少症で出血性粘膜合併症を呈した症例を報告した。一般的な原因は除外されたため、免疫機構が関与していると結論づけた。コルチコイドは有害であると考えられたため，免疫グロブリンの静脈内投与で治療したところ，後の再発はなかった．

We described three COVID-19-infected patients with profound immune thrombocytopenia causing haemorrhagic mucocutaneous complications. We conclude that an immune mechanism was responsible as common causes were excluded. Since corticoids were considered harmful in the circumstances, the patients were successfully treated with intravenous immunoglobulins without later relapse.

学習ポイント:

COVID-19感染の重症度と出血性症候群の重症度は相関していない。軽症のCOVID-19感染における血小板減少症は自己免疫機構を持っていると思われる。

LEARNING POINTS: The severity of haemorrhagic syndrome is not correlated with the severity of COVID-19 infection.Thrombocytopenia in mild COVID-19 infection seems to have an autoimmune mechanism.Intravenous immunoglobulins (1 g/kg) should be the first line of treatment.

© EFIM 2020.